Medical Need of Oral Anti-coagulant Reversal in Japan: Epidemiological Assessment of Head Trauma, Fracture, and Emergency Surgery Using Large Scale Claims Database (Please Note That This Study Contains no Patients Treated With Idarucizumab Although the Study Number Begins With 1321; the Study Contains Only Patients Treated With OACs, Namely Warfarin, Dabigatran, Edoxaban, Apixaban, Rivaroxaban, Edoxaban)
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 19 Sep 2017 Planned End Date changed from 28 Sep 2017 to 14 Dec 2017.
- 19 Sep 2017 Planned primary completion date changed from 20 Sep 2017 to 30 Nov 2017.
- 19 Sep 2017 Planned initiation date changed from 31 Aug 2017 to 6 Oct 2017.